Very interestingly, a recent seminal study demonstrated that the PKCα‐ZFP64‐CSF1 axis drives an immunosuppressive microenvironment and that inhibition of PKCα is capable of enhancing the efficacy of anti‐PD‐1 treatment via reshaping the tumour immune microenvironment [54]. Here, PRKCA is linked to neoplasm.